Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions
© 2022 British Pharmacological Society..
AIMS: The aim of this study was to develop a population pharmacokinetic (PK) model to simultaneously describe both total and unbound concentrations of ciprofol and its major glucuronide metabolite, M4, and to link it to the population pharmacodynamics (PD) model in subjects with various renal functions.
METHODS: A total of 401 and 459 pairs of total and unbound plasma concentrations of ciprofol and M4, respectively, as well as 2190 bispectral index (BIS) data from 24 Chinese subjects with various renal functions were available. Covariates that may potentially contribute to the PK and PD variability of ciprofol were screened using a stepwise procedure. The optimal ciprofol induction dosing regimen was determined by model-based simulations.
RESULTS: The PK of unbound ciprofol could best be described by a three-compartment model, while a two-compartment model could adequately describe unbound M4 PK. The concentrations of total and unbound ciprofol and M4 were linked using a linear protein binding model. The relationship between plasma concentrations of ciprofol and BIS data was best described by an inhibitory sigmoidal Emax model with a two-compartment biophase distribution compartment. Hemoglobin was the identified covariate determining the central compartment clearance of ciprofol; uric acid was a covariate affecting the central compartment clearance of M4 and protein binding rate, kB . The included covariates had no effect on the PD of ciprofol. Simulation results indicated that the label-recommended dose regimen was adequate for anaesthesia induction.
CONCLUSIONS: The developed model fully characterized the population PK and PD profiles of ciprofol. No dose adjustment is required in patients with mild and moderate renal impairment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
British journal of clinical pharmacology - 89(2023), 3 vom: 01. März, Seite 1139-1151 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Shuai-Bing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anaesthesia |
|---|
| Anmerkungen: |
Date Completed 16.02.2023 Date Revised 29.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bcp.15561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34733024X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34733024X | ||
| 003 | DE-627 | ||
| 005 | 20231226033554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bcp.15561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM34733024X | ||
| 035 | |a (NLM)36217805 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Shuai-Bing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.02.2023 | ||
| 500 | |a Date Revised 29.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 British Pharmacological Society. | ||
| 520 | |a AIMS: The aim of this study was to develop a population pharmacokinetic (PK) model to simultaneously describe both total and unbound concentrations of ciprofol and its major glucuronide metabolite, M4, and to link it to the population pharmacodynamics (PD) model in subjects with various renal functions | ||
| 520 | |a METHODS: A total of 401 and 459 pairs of total and unbound plasma concentrations of ciprofol and M4, respectively, as well as 2190 bispectral index (BIS) data from 24 Chinese subjects with various renal functions were available. Covariates that may potentially contribute to the PK and PD variability of ciprofol were screened using a stepwise procedure. The optimal ciprofol induction dosing regimen was determined by model-based simulations | ||
| 520 | |a RESULTS: The PK of unbound ciprofol could best be described by a three-compartment model, while a two-compartment model could adequately describe unbound M4 PK. The concentrations of total and unbound ciprofol and M4 were linked using a linear protein binding model. The relationship between plasma concentrations of ciprofol and BIS data was best described by an inhibitory sigmoidal Emax model with a two-compartment biophase distribution compartment. Hemoglobin was the identified covariate determining the central compartment clearance of ciprofol; uric acid was a covariate affecting the central compartment clearance of M4 and protein binding rate, kB . The included covariates had no effect on the PD of ciprofol. Simulation results indicated that the label-recommended dose regimen was adequate for anaesthesia induction | ||
| 520 | |a CONCLUSIONS: The developed model fully characterized the population PK and PD profiles of ciprofol. No dose adjustment is required in patients with mild and moderate renal impairment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a anaesthesia | |
| 650 | 4 | |a clinical pharmacology | |
| 650 | 4 | |a nonlinear models | |
| 650 | 4 | |a population pharmacodynamics | |
| 650 | 4 | |a population pharmacokinetics | |
| 700 | 1 | |a Yao, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jian-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Ying-Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dong-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Su-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Su-Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xu |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Pang-Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiao-Jian |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhang-Suo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of clinical pharmacology |d 1974 |g 89(2023), 3 vom: 01. März, Seite 1139-1151 |w (DE-627)NLM000097799 |x 1365-2125 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2023 |g number:3 |g day:01 |g month:03 |g pages:1139-1151 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bcp.15561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2023 |e 3 |b 01 |c 03 |h 1139-1151 | ||